Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 17/20 | 0.61 |
| ▸ | RARB | P10826 | 9/20 | 0.61 |
| ▸ | RARA | P10276 | 9/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958560 | 0.97 | RARG (0.61) | RARGRARBRARARXRAHRH3 | |
| SCHEMBL958848 | 0.97 | RARG (0.59) | RARGRARBRARARXRA | |
| SCHEMBL958842 | 0.91 | RARG (0.60) | RARGRARBRARARXRA | |
| SCHEMBL955654 | 0.90 | RARG (0.64) | RARGRARBRARARXRA | |
| SCHEMBL955219 | 0.89 | RARG (0.63) | RARGRARBRARARXRA | |
| SCHEMBL956218 | 0.89 | RARG (0.75) | RARGRARBRARARXRA | |
| SCHEMBL955382 | 0.89 | RARG (0.62) | RARGRARBRARARXRA | |
| SCHEMBL957141 | 0.89 | RARG (0.62) | RARGRARBRARARXRA | |
| SCHEMBL955754 | 0.88 | RARG (0.58) | RARGRARBRARARXRA | |
| SCHEMBL958855 | 0.88 | RARG (0.61) | RARGRARBRARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872026-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-18 | — | — | US | claimed |
| EP-1692093-B1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2008-11-19 | — | — | EP | claimed |
| US-20070021473-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-01-25 | — | — | US | claimed |
| EP-1692093-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-23 | — | — | EP | claimed |
| WO-2005056516-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | claimed |
| US-7872026-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-18 | — | — | US | disclosed |
| EP-1692093-B1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2008-11-19 | — | — | EP | disclosed |
| US-20070021473-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1692093-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056516-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021473-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | RARG 3/4885RARB 2/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.